がん免疫療法の世界市場 - 成長、動向、予測（2019年～2024年）
Cancer Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||911946|
|出版日||ページ情報||英文 115 Pages
|がん免疫療法の世界市場 - 成長、動向、予測（2019年～2024年） Cancer Immunotherapy Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年09月01日||ページ情報: 英文 115 Pages||
Cancer Immunotherapy Market is expected to witness a CAGR of 12.2% during the forecast period. Certain factors that are driving the market are R&D activities, increasing effectivity and accuracy of newer therapies, growing prevalence of cancer.
The incidence of cancer is increasing significantly and has been the major factor for the growth of the cancer immunotherapy market. Cancer damages the immune system, as cancer cells produce the self-antigen. The cancer immunotherapy plays a vital role in the maintenance of the immune system, and it targets the infectious agents that may cause cancer through the production of the antibodies. Cancer Immunotherapy is considered as new therapy and is not popular compared to the other alternative therapeutic drugs. However, cancer immunotherapy has shown great potential over the past few years. Also, with healthcare physicians looking for the alternative therapies due to the huge burden of cancer cases and side effects of the present therapies, the market of cancer immunotherapy is expected to grow with a high growth rate during the forecast period.
However, in the expanding market for medical therapies, there are stringent regulatory policies in place to ensure the safety of therapies. The FDA review process takes twice as much as time as European regulatory commissions' review bodies. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market.
Immunotherapy is a treatment that uses certain parts of a person's immune system to fight diseases such as cancer. This can be done either by stimulating one's own immune system to work harder and smarter to attack cancer cells, or by giving one immune system components, such as man-made immune system proteins.
Cancer Vaccines are Expected to Show Lucrative Growth Opportunity in the Therapy Type Segment
Various advancements are taking place in the field of cancer vaccines owing to the ongoing research studies all across the globe. Cancer vaccines can majorly be classified into two types i.e. preventive vaccines and therapeutic vaccines. Preventive cancer vaccine or prophylactic vaccines are the vaccines that are intended to prevent the development of cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. These vaccines are similar to a traditional vaccine that helps in preventing infectious diseases, such as polio and measles, by protecting the body against infections. Most of the preventive vaccines stimulate the production of antibodies, which bind to the specifically targeted microbes and block their ability to cause infection.
North America Dominates the Market and Expected to do Same in the Forecasted Period
This is due to the high prevalence of cancer, along with developed healthcare infrastructure in the region. According to the National Cancer Institute, preventive cancer vaccines were approved to treat cancers caused by the use of vaccines, namely Human papillomavirus (HPV) vaccines and the Hepatitis B virus (HBV). However, there are many other immunotherapies that were approved by the FDA for the prevention of cancer. In April 2010, the first cancer treatment vaccine, called sipuleucel-T (Provenge), was approved by the FDA. This vaccine was approved for use in men with metastatic prostate cancer. It was designed to stimulate an immune response to prostatic acid phosphatase (PAP), which is an antigen found in most prostate cancer cells. Moreover, in October 2015, the first oncolytic virus therapy, called talimogene laherparepvec (T-VEC, or Imlygic), was also approved by the FDA. This vaccine is used for the treatment of metastatic melanoma that cannot be surgically removed.
The Cancer Immunotherapy market is highly competitive and consists of a few major players. Companies like Amgen Inc., Astellas Pharma, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Co., F. Hoffman La Roche, Merck and Co., Novartis, OSE Immunotherapeutics, among others, hold the substantial market share in the Cancer Immunotherapy market.